title: Application of the IDSA guidelines for the use of antimicrobial agents in neutropenic patients: impact on reducing the use of glycopeptides.
abstract: We evaluated the impact of applying the Infectious Diseases Society of America guidelines for febrile neutropenic patients in reducing the use of glycopeptides. Forty-five prior episodes of febrile neutropenia were compared to 97 episodes seen after application of the guidelines. Glycopeptide use was reduced from 73% to 43% of episodes (P=.0008), without changes in outcome.
authors.affiliation: University Hospital, Universidade Federal do Rio de Janeiro, Brazil.
authors.forename: M
authors.initials: M
authors.lastname: Nucci
authors.forename: M
authors.initials: M
authors.lastname: Landau
authors.forename: F
authors.initials: F
authors.lastname: Silveira
authors.forename: N
authors.initials: N
authors.lastname: Spector
authors.forename: W
authors.initials: W
authors.lastname: Pulcheri
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000583:Amikacin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001938:Brazil; D000077723:Cefepime; D002442:Ceftazidime / Q000627:therapeutic use; D002511:Cephalosporins / Q000008:administration & dosage; D002648:Child; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D005260:Female; D005334:Fever / Q000150:complications / Q000188:drug therapy*; D006784:Hospitals, Teaching; D006801:Humans; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000150:complications / Q000188:drug therapy*; D010068:Oxacillin / Q000008:administration & dosage; D017410:Practice Guidelines as Topic; D017334:Teicoplanin / Q000627:therapeutic use; D016896:Treatment Outcome; D014640:Vancomycin / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D017334:Teicoplanin; D014640:Vancomycin; D000077723:Cefepime; D000583:Amikacin; D002442:Ceftazidime; D010068:Oxacillin